Assessment of Echocardiography and Biomarkers for the Extended Prediction of Cardiotoxicity in Patients Treated With Anthracyclines, Taxanes, and Trastuzumab

摘要: Background— Because cancer patients survive longer, the impact of cardiotoxicity associated with use treatments escalates. The present study investigates whether early alterations myocardial strain and blood biomarkers predict incident in breast during treatment anthracyclines, taxanes, trastuzumab. Methods Results— Eighty-one women newly diagnosed human epidermal growth factor receptor 2–positive cancer, treated anthracyclines followed by taxanes trastuzumab were enrolled to be evaluated every 3 months their therapy (total 15 months) using echocardiograms samples. Left ventricular ejection fraction, peak systolic longitudinal, radial, circumferential calculated. Ultrasensitive troponin I, N-terminal pro–B-type natriuretic peptide, interleukin family member (ST2) also measured. fraction decreased (64 ± 5% 59 6%; P <0.0001) over months. Twenty-six (32%, [22%–43%]) developed as defined Cardiac Review Evaluation Committee Reviewing Trastuzumab; these patients, 5 (6%, [2%–14%]) had symptoms heart failure. Peak longitudinal ultrasensitive I measured at completion predicted subsequent development cardiotoxicity; no significant associations observed for left ST2. Longitudinal was <19% all who later failure. Conclusions— In trastuzumab, are useful prediction may help guide avoid cardiac side-effects.